Journal
ANNUAL REVIEW OF GENETICS, VOL 49
Volume 49, Issue -, Pages 47-70Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-genet-112414-054926
Keywords
pluripotent stem cells; genetic correction; programmable nuclease; TALEN; CRISPR-Cas9
Categories
Funding
- Grants-in-Aid for Scientific Research [15H05581] Funding Source: KAKEN
Ask authors/readers for more resources
The advent of induced pluripotent stem (iPS) cells has opened up numerous avenues of opportunity for cell therapy, including the initiation in September 2014 of the first human clinical trial to treat dry age-related macular degeneration. In parallel, advances in genome-editing technologies by site-specific nucleases have dramatically improved our ability to edit endogenous genomic sequences at targeted sites of interest. In fact, clinical trials have already begun to implement this technology to control HIV infection. Genome editing in iPS cells is a powerful tool and enables researchers to investigate the intricacies of the human genome in a dish. In the near future, the groundwork laid by such an approach may expand the possibilities of gene therapy for treating congenital disorders. In this review, we summarize the exciting progress being made in the utilization of genomic editing technologies in pluripotent stem cells and discuss remaining challenges toward gene therapy applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available